• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Aspire Trial Failure And Expense Cut Plans

    Simply Wall St·09/05/2026 19:25:37
    语音播报
    • In early September 2026, Ultragenyx Pharmaceutical reported that its Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary and key secondary endpoints, and the company is now evaluating the program and planning significant expense reductions while maintaining support for its commercial portfolio.
    • At the same time, Ultragenyx secured FDA approval and a rare pediatric disease priority review voucher for its GENGLYCOS gene therapy for glycogen storage disease type Ia, underscoring a contrast between a major late-stage setback and progress in its growing gene therapy business.
    • Next, we’ll examine how the failed Aspire trial and potential expense cuts could reshape Ultragenyx’s previously growth-focused investment narrative.

    AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Ultragenyx Pharmaceutical Investment Narrative Recap

    To own Ultragenyx today, you really have to believe that its commercial rare-disease portfolio and emerging gene therapy franchises can eventually overcome ongoing losses and a short cash runway. The Aspire failure directly undercuts one of the company’s previously highlighted late-stage catalysts and intensifies the current key risk around profitability and funding flexibility, even as near-term value now leans more on execution for already approved products and gene therapies.

    The most relevant recent announcement is the FDA approval of GENGLYCOS for glycogen storage disease type Ia, along with the award of a rare pediatric disease priority review voucher. This strengthens Ultragenyx’s gene therapy credentials and adds a new commercial asset just as management signals significant expense reductions, making GENGLYCOS’s real-world uptake and voucher monetization an important counterbalance to the Aspire setback in the near term.

    Yet, against the promise of new gene therapies and fresh revenue streams, investors should be aware that persistent losses and a limited cash runway could still...

    Read the full narrative on Ultragenyx Pharmaceutical (it's free!)

    Ultragenyx Pharmaceutical's narrative projects $1.2 billion revenue and $43.8 million earnings by 2029.

    Uncover how Ultragenyx Pharmaceutical's forecasts yield a $27.00 fair value, a 76% upside to its current price.

    Exploring Other Perspectives

    RARE 1-Year Stock Price Chart
    RARE 1-Year Stock Price Chart

    Before this setback, the most optimistic analysts were counting on about US$1.8 billion of revenue and roughly US$468.4 million of earnings by 2029, so this Aspire miss may force you to reconsider how much weight you put on rapid adoption and concentrated product bets, and whether those bullish expectations still feel realistic.

    Explore 5 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be a potential multi-bagger!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.